Porter, Paul http://orcid.org/0000-0001-9051-589X
Abeyratne, Udantha
Swarnkar, Vinayak
Tan, Jamie
Ng, Ti-wan
Brisbane, Joanna M. http://orcid.org/0000-0003-3364-5414
Speldewinde, Deirdre
Choveaux, Jennifer
Sharan, Roneel
Kosasih, Keegan
Della, Phillip
Article History
Received: 20 October 2018
Accepted: 8 April 2019
First Online: 6 June 2019
Ethics approval and consent to participate
: Ethical approval was obtained from the Human Research Ethics Committees of Princess Margaret Hospital (2015030EP), Joondalup Health Campus (1501), Curtin University (HRE2018–0016) and The University of Queensland (2015000395 / 2016.01.179). All participants parents or guardians signed a consent to participate form.
: PP and UA are scientific advisors and shareholders in ResApp Health (RAP). UA is RAP’s Chief Scientist. RAP is commercialising the technology under license from the University of Queensland, where UA is employed. UA and VS are named inventors of the UQ technology. DS, JB and PD declare no competing interests. TN, JT, VS and JC are shareholders in RAP.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.